登录

Ruiyi Medical Closes ¥10M Private Placement

作者: Mailman 2021-05-28 16:20
瑞一科技
http://www.ruiyitech.com/
企业数据由 动脉橙 提供支持
医药中间体研究、开发商 | 新三板定增 | 运营中
中国-上海
2023-03-06
融资金额:RMB¥1.03亿
怀格资本
查看

(VCBeat) May. 6, 2021 -- Shanghai RuiYi Medical Tech Co., Ltd. ("Ruiyi Medical"), a Chinese company focused on medical organosilicon products, announced that it has closed its private placement of tens of millions, led by Huaige Capital, with participation from Hongbo Capital. According to Ruiyi Medical, this private placement will further enhance the company's financial strength to accelerate scale expansion and business development, and improve its overall competitiveness."


Ruiyi Medical was founded in May, 2006 and composed of Ruiyi Shanghai and Ruiyi Haimen. It is a high-tech company that focuses on manufacturing and R&D outsourcing services of new-type medical organosilicon intermediates, reagents for organic synthesis and pharmaceutical raw material intermediates. Ruiyi Medical is a leading company in the R&D and production of medical organosilicon products in China, meanwhile, it is also the main supplier in the global market of medical organosilicon products.


With a number of special technologies, Ruiyi Medical has developed a number of first-of-its-kind reagents and molecular building blocks of new drugs in China. Its star products have been exclusively supplied to a number of large international pharmaceutical enterprises for a long time, and it has maintained long-term close cooperation with well-known domestic and foreign drug R&D enterprises. After years of development, Ruiyi Medical has grown into a CDMO serving well-known pharmaceutical companies at home and abroad, providing key intermediates and functional molecular building blocks in clinical I, II and III stages and commercialization.


>>>>

About Huaige Capital


Founded in 2016 by Mr. Kai Wang. Huaige Capital is a Shanghai-headquartered venture capital focusing on the healthcare sector (medical devices, innovative drugs, biologics, outsourcing services, etc.), and preferably invest at early or growth stage. They foster "active investment" as well as "in-depth value-added services" as their principal strategy, and aim to be a boutique venture capital within the healthcare sector. In line with the spirit of "integration and specialization", the company is committed to creating greater value for both its investors and its portfolio companies.


>>>>

About Hongbo Capital


Hongbo Capital is a private equity investment fund manager jointly established by state-owned financial institutions and investment banks. The company is committed to providing investment and financing, industrial integration, strategic management and other financial services for its portfolio.

相关赛道 研发制造外包
文章标签 CDMO医药投融资
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

2023创新药及供应链白皮书:解读近400起融资事件,百余条临床管线与BD并购

药明合联、上海维亚、金斯瑞蓬勃,今年为何CXO企业都想分拆上市?

【首发】核酸药物CDMO深耕者——欧利生物完成数千万元Pre-A轮融资

【首发】抗体和重组蛋白药物CDMO皓阳生物完成超8000万元A轮融资,布局一站式药物开发

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Xukang Medical·Yikon Genomics Closes ¥250 Million in Series D

2021-05-28
下一篇

Weihansi Biopharma Raises ¥100M in Series Pre-B Funding Round

2021-05-28